BioSpace News Archive

CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company’’ or ''CLS’’, a diversified cannabis company operating as Cannabis Life Sciences, today announced its financial and operational results for the months of May and June 2020 with net revenues of $1,011,907 USD and $1,102,498 USD, respectively.

Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing new classes of synthetic anti-infectives, today announced the appointment of Alan W. Dunton, M.D., to its Board of Directors as an independent Non-Executive Director and as a member of the Company’s Audit & Risk and Remuneration & Nomination Committees. “On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors,” stated Dr. John Pre

As responses to the COVID-19 pandemic evolve, Avitecture ® provided a smart, simple, and safe solution to help manage the return of employees and visitors to one of America’s largest corporations at its McLean, Virginia headquarters. Virginia , Maryland , and the District of Columbia are entering new phases of reopening and p

Lamassu Pharma LLC, a privately held Biotech announced today it has received $1.5 million in Small Business Innovation Research (SBIR) grant funding from the National Institutes of Health (NIH). This will be used for further development of its lead therapeutic compound, RABI-767, a novel small molecule lipase inhibitor licensed from t

SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic solid tumors. Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab. The trial is conducted in partnership with Cytune Pharma. Early results from the ongoin

10x Genomics  (Nasdaq: TXG) strengthened the research toolkit of scientists around the globe today with the launch of its Chromium Single Cell Immune Profiling v2 product. The new product extends the capabilities of the original version, supporting fundamental breakthroughs in immunology, oncology, autoimmunity, inflammation, transplant biology, and infectious diseases. It also significantly builds on the existing product that is bein

Partnership promotes image exchange with a true zero footprint; improves interoperability between providers

USANA ® , a leader in cellular nutrition, is honored to receive another seal of approval from third-party tester ConsumerLab.com . This time for its flagship supplement, USANA CellSentials .

Revamp Medical, a medical device company developing a percutaneous device for the treatment of acute heart failure (AHF), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Doraya™ device. The Doraya is a temporary catheter, placed in the Inferior Vena Cava below the r

Path to Better Health Study also reveals desire for digital health care solutions to support chronic care, mental health needs.